Glutamatergic Modulators · · · Sustained Antidepressant ·

项目来源

美国卫生和人类服务部基金(HHS)

项目主持人

ZARATE, CARLOS

项目受资助机构

NATIONAL INSTITUTE · · ·

立项年度

2020

立项时间

未公开

项目编号

1ZIAMH00285716

项目级别

国家级

研究期限

未知 / 未知

受资助金额

3019176.00美元

学科

Behavioral and · · · Imaging; Brain · · · Clinical Trials · · · Depression; Major · · · Health; Mental · · · Mental Illness;

学科代码

未公开

基金类别

INTRAMURAL RESEARCH

关键词

AMPA Receptors ; Acids ; Acute ; Age ; Anterior ; Antidepressive · · · Disorder ; Brain ; Brain-Derived Neurotrophic · · · life ; Chronic ; Clinical ; Clinical Treatment ; Cross-Over · · · suicidal ; Frequencies ; Functional Magnetic · ·

参与者

ZARATE, CARLOS ·

参与机构

NATIONAL INSTITUTE · · ·

项目标书摘要:Our results · · · glutamatergic system · · · the mechanism · · · rapid antidepressant · · · may be · · · for developing · · · rapid and · · · individuals who · · · and suicidal · · · the glutamatergic · · · in rapid,robust · · · antidepressant,antisuicidal,and antianhedonic · · · occurred within · · · lasted approximately · · · rapid response · · · disorder):protocols 04-M-0222(NCT00088699),17-M-0060(NCT03065335),and · · · the neural · · · and molecular · · · antidepressant response · · · antagonist ketamine · · · major depressive · · · examine the · · · ketamine,and 2)to · · · antidepressant response · · · both major · · · bipolar disorder · · · data/outcome measures:clinical(e.g.,family · · · MEG,electroencephalography EEG),neuropsychological,and · · · robust neuropharmacodynamic · · · neuropharmacodynamic imaging(fMRI+EEG · · · 0.5 mg/kg · · · placebo administered · · · 4)To understand · · · AMPA receptors · · · response.Secondary aims:To · · · in synaptic · · · in response · · · in association · · · sleep EEG · · · better antidepressant · · · past year:1.The · · · on Electrophysiological · · · Depressive Disorder:Major · · · disabling.Only about · · · to a · · · around 30%of · · · as"treatment-resistant"after failing · · · multiple adequate · · · target monoaminergic · · · N-methyl-D-aspartate(NMDA)antagonist that · · · antidepressant effects · · · or intranasally.While · · · that ketamine · · · via enhanced-amino-3-hydroxy-5-methyl-4-isoxazolepropionic · · · relieving depressive · · · unknown.This study · · · recordings after · · · placebo infusions · · · connectivity using · · · correlation technique · · · frequency bands24 · · · unmedicated participants · · · part in · · · of 0.5 · · · results indicated · · · in connectivity · · · and beta · · · not correlate · · · antidepressant response.In · · · ketamine's antidepressant · · · participants was · · · connectivity for · · · bands,with HVs · · · showing connectivity · · · ketamine responders · · · in connectivity.These · · · functional subtypes · · · suggest that · · · ketamine are · · · and non-responders.2.Ketamine · · · power in · · · for treatment-resistant · · · dose of(R,S)-ketamine(ketamine)exerts · · · antidepressant effects.We · · · antidepressant effects · · · increased cortical · · · study examined · · · ketamine metabolites,clinical · · · power changes · · · 18-65)with treatment-resistant · · · a single · · · 40 min.Plasma · · · HNKs were · · · 230 min · · · 3 days · · · evaluated ketamine · · · of antidepressant · · · and their · · · whole-brain magnetoencephalography(MEG)gamma · · · post-infusion.We found · · · positively predicted · · · at Day · · · inverse relationship · · · concentration and · · · three and · · · increased(2S,6S;2R,6R)-HNK maximum · · · with increased · · · global brain · · · imaging marker · · · preprocessing strategies · · · treatment:Major depressive · · · altered global · · · via resting-state · · · imaging(rsfMRI).Previous studies · · · treatment with · · · GBC changes · · · and cingulate · · · of GBC · · · imaging marker.These · · · via global · · · analyzed in · · · MDD and · · · baseline,post-placebo,and post-ketamine.Reduced · · · in individuals · · · at baseline · · · and medial · · · as in · · · only after · · · signal.Ketamine had · · · to baseline · · · either group · · · results concur · · · that used · · · GBC.Further investigations · · · disease-specific components · · · signals that · · · results and · · · a potential · · · MDD.4.Ketamine on · · · depressive symptoms:This · · · effects of · · · dose of · · · depressive symptoms(measured · · · Depression Rating · · · the MADRS5),and · · · the Scale · · · were from · · · treatment-resistant major · · · sizes were · · · than atypical · · · 1 postinfusion.Ketamine · · · treat both · · · atypical symptoms · · · have early · · · the former.5.The · · · of COVID-19 · · · Workers Protocol(P205022:PI:Zarate,Carlos)completed · · · collection and · · · will re-contact · · · month follow-up · · · year.In total,over · · · ratings related · · · and mental · · · PTSD.We are · · · process of · · · paper,which will · · · of COVID-19 · · · in HCWs.

项目持续时间

16 years

  • 排序方式:
  • 8
  • /
  • 1.Th···id···im···ti···ho···ne··· a···ci···d ···h ···fe···ti···an···ep···sa···an···nt···nh···ni···es···se··· k···mi···in···po··· d···es···n ··· n···ma··· d···es···e ···or···

    • 关键词:
    • Major depressive disorder; Bipolar depression; Treatment-resistantdepression; Ketamine; Thyroid-stimulating hormone;TREATMENT-RESISTANT DEPRESSION; D-ASPARTATE ANTAGONIST; EFFICACY; TSH;HYPOTHYROIDISM; LEVOTHYROXINE; DEFINITION; TRIAL; SCALE
    • Gr···e,···ad···.;···tm··· A···;Y···n,···fi···Kv···a,···rk···;W···, ···li···.;···i,···ni···ee···ei···De···Za···e ··· C···os···
    • 《JO···AL··· A···CT··· D···RD···》
    • 2026年
    • 395卷
    • 期刊

    Ba···ro···: ···cl···ca··· u···ul···om···er···ur···tl···re···t ···id···es···t ···po··· t···et···ne··· t···tm···-r···st··· m···r ···re···ve···so···r ···D)··· b···la···is···er···D)···hi···tu···in···ti···ed···et··· b···li···th···id···im···ti···ho···ne···SH···ev··· a···as···ia··· w··· k···mi···s ···id···es···t,···ti···he···ic···nd···ti···ic···l ···ec··· M···od···Th···wa··· s···nd··· e···or···ry···al···s ···da···dr··· f··· f··· N···sp···or··· r···om···d,···ac···-c···ro···d,···ub···bl··· c···so··· s···ie···f ···am··· i···np···en···wi···cu···nt···D ···= ··· o···ip···r ···re···on··· =···).···se···e ··· l···ls···re···as···d ···or···he···rs···nt···en··· s···ne··· k···mi···in···io···0.···g/···. ···wo···ek···sh··· p···ed···th···ec··· i···si··· D···es···n ··· a···do··· w··· m···ur···wi···th···on···me···& ···ng···er···ep···si···Ra···g ···le···AD··· a···th···na···-H···lt···Pl···ur···ca··· r···ec···el···Su···da···de···on···I)···s ···su··· a··· w···ht···av···ge··· t···Be···De···ss··· I···nt··· a···th···AD···su···de···em···Li···r ···ed···de···we···us···to···al···e ···el··· T···le···s ···a ···er···r ···re···ns···o ···am··· (···su···la···o)···on···ll··· f···th···id···se···, ···hi···us···an···ep···si···se···it···t ··· m···an···ay···, ···an··· p···-i···si··· R···lt···In···di···ua···wi···BD···ig··· b···li···TS···ev··· w··· a···ci···d ···h ···at···de···as···in···e ···er··· o···ep···si···(d···*T··· p···0.···7)···d ···ed···a ···ug···H,···< ···00···sy···om···os···et···ne···SH···ve···we···no···ss···at···wi···ch···es··· d···es···n,···he···ia···r ···se···it···n ··· p···-k···mi··· C···lu···n:···se···e ··· l···ls···re···so···te···it···et···ne···an···ep···sa···an···nt···nh···ni···ff···s ···BD···t ··· M··· T···e ···di··· s···es···ha···SH···y ···ve··· a···ed···iv···io···ke···f ···po··· a···hi···ig···a ···en···l ···ro···gl···ma···in···en···in···ta···e'···ec···is···f ···io··

    ...
  • 2.Tr···di···os··· a···ra···ns··· w···e ···te···ic···tr···ur···ss···at···wi···su···da···ho···ts···d ···av···rs··· t···EN···A ···ci··· T···gh···an···eh···ou···co···rt···.

    • va···el···, ···ra···Co···, ···la···ja···ur···;D···er···n,···ri···;V···a,···ca···Sa···e,···nn···S;···nd···, ···a ···eh···an···Ni···ha···u,···ys···H;···po···Ad···n ···al···en···au··· E···ar··· I···id···ex···er···in···ye···Ar···la···os···al···d,···iz···th···Ba···, ···is···ar···u,···rl···a;···go··· Z···ep···ue···Jo···n;···ed···i,···an···co···rg··· K···s;···te···, ···nc···ro···, ···ha···a;···al···ve··· M···el···rv···a,···mo···ol··· R···in···nn···y,···lm···Co···bl···Em···ue···;C···te···Ph···pp···ou···Du···sn···Ba···st···re···-F···rr···Be···ic···Cu···n,···th··· R···nn···sk···Ud···ev···un···er···;D···-Z···ag···An···;D···ze···or···le···F;···ns···en···er···Fa··· N···r;···nk···lu···, ···a;···ed···, ···mi···Go···b,···n ···ro···wo··· N···e ···ro···er···Do···ik···je···To···;H···um···le···de···;H···es···f,···rc···ic···, ··· B···ra··· Y···iy···;H···Ti···ny···Ik···zu···uk···or···o,···an···ps··· J···th···C;···be···uk···ac···sk···An···a ···ol···t,···br···;K···he···Ti···Kl··· M···ss···oo···it···Sh···-M···el···Kr···, ···a;···g,···el··· B···, ···an···le···eh···El···be···J;··· M···;L···ar···El···be···T ···op···Ja···il··· C···os···xi···, ···n ···cI···sh···nd··· M···La···li···Ka··· A···Wh···ey···ea···;M···er···Su···ne···ll···, ···sa···tc···l,···il···B;···ng···Be···n;···ad··· I···;N···an···St···r;···e,···il···Or···-G···ia··· l···oz···ic···;P··· P···o ···er···a,···br···o;···as···ab···io···ra···Fe···ic···ol···i,···ra···in···rg···nd··· E···be···, ···ri···om···-G···ia···af···;S···he···Ma···ew···Sa···, ···va··· A···nd···An···La···a;···lg···, ···l ···hi···u,···ji···ol···, ···ry···So···s,···ir···Sp···et··· G···fr···o;···gl···St···e,···St···, ···de···e;···in···an···St···be···en···in···ut···er···Le···ho···-O···th··· F···ia···se···n,···ul···al···eg··· R···in···le···a-···ev···y,···ha···;W···er···er···ai···, ···do···al···, ···ti···ha···y,···at··· C···, ···-J···an···To···T;···at···Ca···s ···ug···, ···re···nt···oa···, ···va···B;··· H···in···, ···s;··· R···j,···nn··· H···n ··· W··· N···va···er···rf···St···n;···mp···, ···l ···lu···rg···il··· P···n ···me···, ···e-···ra···nt···a,···gu···E;···an···d,···da···hm···, ···nn·
    • 《me···iv···th···re···nt···rv···fo···ea··· s···nc··》
    • 2024年
    • 期刊

    Pr···ou···tu···s ···e ···ge···d ···t ···er···on···n ···te···tt···(W···mi···st···tu···ar···mp···at···in···ic···l ···ug··· a···be···io··· (···s)···ow···r,···nd···s ···di···si···te···r ···gi···(D··· s···ie···av···ee···nc···is···t.··· t··· l···e-···le···ga···al···s ···du···d ···th···NI··· S···id···Th···ht···nd···ha···ur···EN···A-···) ···so···um···e ···mi··· W···lt···ti··· a···ci···d ···h ···s.···ta···oc···in···as···an···di··· a···ss···te···an···es···in···M ···ro···uc···e ···su··· (···ct···al···is···op···ax··· d···us···ty···ea···if···iv··· a···ra···l ···fu···it···fo···5 ···tr···s ···e ···le···cr··· 4···oh···s.··· c···ar···th··· m···ur···am··· i···vi···ls···th···ps···ia···c ···gn···s ··· l···ti···hi···ry··· s···id···tt···t ···65···me···ag···5.···4.···fe···e=···8%···in···id···s ···h ···sy···at··· d···no··· b···no···B ···e.···li···al···nt···s;···18··· m··· a···34···.8···em···=5···%)···nd···di···ua···wi···no···nt···di···de···ia···si···nd··· S···(i···, ···lt···co···ol···n=···; ···n ···=2···±1···; ···al···2.···. ···al···co···re···he···me···re···mo···in···id···s ···h ···en···ui···al···ea···n ···71···me···ag···6.···5.···fe···e=···1%···cl···ca···on···ls···=1···; ···n ···=3···±1···; ···al···3.···, ··· h···th···on···ls···=1···; ···n ···= ···6±···5;···ma···61···).··· f···d ···tl···ut···at···ic···y ···ni···an···ff···s,···ch··· l···r ···ct···al···is···op···ss···at···wi···a ···to···of···ic··· a···mp···ov···an···bo···th···ff··· o···sy···at··· d···no···. ···se···fe··· w··· s···ng··· i···he···ro···ra···ta···ha···ic···di···on···or···/s···a ···mi···is···or··· c···os···an···up···or···ng···di··· f···ic···s.···fe···si··· w··· s···l ···he··· d···0.···. ···en···ui···al···ea···n ··· n···as···ia··· w··· a···ra···ns··· W···ic···tr···ur···Th···la···-s···e ···rd···te···eg···na···is···ve···d ···tl···eg···al···d ···ba···lt···ti··· i···M ···ro···uc···e ···in···id···s ···h ···is···y ···su···de···te···. ···gi···in···st···es···e ···de···o ···fi···wh···er···es···lt···ti··· a···a ···k ···to···or···ic···l ···av···r.

    ...
  • 3.Re···iv···ff···iv···ss··· a···de···ss··· t···tm···s ···tr···me···re···ta···de···ss···: ···ys···at···re···w ··· n···or···et···na···is··· r···om···d ···tr···ed···ia···

    • 关键词:
    • 0 / Antidepressive Agents
    • Sa···ns···oh···Gr···er···nn···at···, ···to···;Z···te···ar··· A···;L···en···ge···Ru···t;···us···hr···op·
    • 《Ne···ps···op···ma···og··· o···ci···pu···ca···n ···th···me···an···ll··· o···eu···sy···ph···ac···gy》
    • 2025年
    • 50卷
    • 6期
    • 期刊

    Th···sy···ma··· r···ew···d ···wo···me···an···si···NM···so···t ···co···re···ff···nt···ti···re···nt···ea···nt···or···ea···nt···si···nt···pr···io···TR···in···de···o ···il···te···id···e-···ed···oi···. ···it···tu···se···h ···Pu···d,···ch···e ···ra··· a···Em···e ···m ···ep···n ···il···ri···3t···20···id···if··· r···om···d,···nt···le···ri··· (···s)··· a···ts···th···pr···io···ho···d ··· r···on··· t···t ···st···o ···id···es···t ···al···al···CT···ad···0 ···ti···an···pe···tu···ar···an···ar···ip···s ···h ···ol···or···yc···ic···pr···io···er···xc···ed···he···ch···e ···k ···Bi···To···2 ··· u··· t···ss··· s···y ···li··· R···on···ra···wa···he···im··· o···om···ea···e.···ds···ti···(O··· u···g ···an··· e···ct···MA···e ···or···. ···m ···4 ···or··· 6···CT···er···nc···ed··· t··· a···ys··· e···mp···in···0,··· p···ic···nt···56···/4···M)···d ···se···at···re···en··· S···of···e ···tr···me··· d···ns···te··· h···er···sp···e ···e ···su···la···o ···sh···tr···me··· e···tr···nv···iv···he···y ···T)···in···cl···, ···ta···rs···ti···at··· (···),···pe···iv···ra···ra···l ···ne··· s···ul···on···TM··· k···mi··· a···ar···pr···le···Rs···ng···fr···1.···95···=[···5;···91···fo···ri···ra···e ···12··· (···CI···.0···40···])···r ···. ···er··· h···ro···ei···of···e ···el···s ···er··· (···47··· (···CI···6.···2%··· O···he···cl···d ···di··· 1···% ···e ···ed··· h···ng···gh···sk··· b···, ···13···s ···in···ow···sk···nd···.3···as···ow··· s··· c···er··· S···ra···ff···iv···re···en···fo···RD···ow···ro···t ···at···t ···ec···ac···s ···co··· (···, ···, ···S,···d ···am···),···d ···er···ho··· p···is··· r···lt···or···me···ut···t ···, ···co··· (···oc···in···ar···pr···le···Th··· f···in···ma···el···ui···ev···nc···as···tr···me···ch···es···r ···. ···dy···gi···at···: ···SP··· (···D4···34···84···© ···4.···e ···ho···).

    ...
  • 4.Mu···-s··· b···hm··· c···si···at··· o···aj···de···ss··· d···rd···us··· m···in···ea···ng··· c···ic···an···ub···ti··· m···ur··

    • 关键词:
    • ALZHEIMERS-DISEASE; CEREBRAL-CORTEX; THICKNESS; HARMONIZATION;ABNORMALITIES; CONNECTIVITY; RELIABILITY; BIOMARKERS; UNIPOLAR; SCANNER
    • Be···, ···di···;E···n-···bn··· T···y;···aj···, ···i;···ma···An···;A···, ···ss···.;···go··· Z···ep···ne···ti···ra···sc···es···er···ia···;B···ow···ob···Ch···, ···is···he···. ···Co···ll···Co···G.···ll··· K···ry···av··· C···st···er···;D···, ···ai···ls···nn···ek···an···Je···fe···.;··· C···hi···. ···Go···, ··· S···et···tl··· I···H.···ab···Ha···J.···oe···ol···Ny···;H···lt··· J···au···ar···on···en···;H···Ti···ny···;M···gi···en···;J···rs··· N···li···ah···ha···Ne···Kl···s-···ga···Bo···e;···po···z,···er···ic···le···nc···er···ho···;L···Me···Li···n,···vi···. ···Ma···st··· F···k ···Me···r,···vi···. ···Me···ni···li···Mu···er···ry···A.···ha···ma···ud···, ···di···L.···nn···, ···nd···. ···H.···le···, ···a;···ar···Cl···t,···it···or···la···ar···J.···zz···El···;R···ma···Li···et···ac···t,···tt··· D···ae···n,···il··· G···ch···te···An···;S··· K···;S···es···ai···.;···in···an···;T···op···os···op··· I···ya···em··· A···ha···an···r ···, ··· J···.;··· d···We···, ···ve···. ···Vo···ke···en···Wh···le···ar···Wi···el···Ka···ri···Wr···t,···rg···t ···Wu···on···;Y···, ···y ···Za···e,···rl···Ve···an···ic···.;···ma··· L···ne···om···n,···ul···;G···-M···on···, ···er··
    • 《SC···TI··· R···RT·》
    • 2024年
    • 14卷
    • 1期
    • 期刊

    Ma···ne···ar···g ···) ···hn···es···ve···in···po···ar··· i···he···ur···ag··· f···d ··· t···he···po···ti···fo···la···fy··· n···op···hi···ic···so···rs···ow···r,···e ···gn···ic···ed···iv···ow···of···e ···st··· a···ri···s ··· b··· l···te···y ···ll···mp···si···, ···k ···re···se···ti···es···da···le···ge···nd··· o···fi···ng···er···we···er···e ···se···mi···io···wi···th···ar···t ···ti···te···mp···si···to···te··· =···65···o ···vi···a ···er···za··· M···la···fi···io···en···ar···f ···or···pr···iv···is···er···DD···si···sh···ow···ne···an···on···ne···mo···s.···ve···in···ra···me···re···ro···ta···rd···d ···GM···na···is···pe···es··· F···Su···r,··· w··· a··· t···la···fy···D ···su···ea···y ···tr··· (··· w··· a···la···d ···ur··· o···ro··· 6··· B···af··· h···on···ng···e ···a,···g.···si···Co···t,···e ···an··· a···ra···dr···ed··· a···ox···te···52···Ac···ac···es···s ···se··· r···om···an···le···s ···e ···o ···er··· i···tr···fi···gr···s ···or···g ···ag···f ···et···nt···pr···an···se···um··· o···pi···es···d ···. ···ur···tu···s ···or···at··· h···er···me···on···br··· i···in···he···yp···ea···es···nd··· u···g ···e ···an··· m···in···nd···ep···ar···g ···ho···ma···ie···mo···en···ra···g ···sp···s.

    ...
  • 5. Re···za···ns··· n···co···ta···e ···io··· f···ti··· a···nd···ma···x ···tr···:s···he···,m···ma···ea···at···s ··· e···ua···n ···st···y ···te···ge···s

  • 6.Cl···ca···be···io···, ··· e···tr···ys···og···l ···fi··· a···g ···on···uu···f ···ci···ri··· e···en···fr···an···pl···t ···oc···io···as·

    • 关键词:
    • dynamic causal modeling; gamma power; implicit association task;ketamine; magnetoencephalography; suicide;AVERSIVE VISUAL-STIMULI; INTRAVENOUS KETAMINE; NEURAL RESPONSES; SCALE;ANTICIPATION; IDEATION; INSULA; DEATH; ACTIVATION; ATTENTION
    • La···ta···, ···ve···.;···be··· J···ic···.;···al···Pa···a ···Wa···an···au···R.···ra···Jr···ar··· A···al···d,···iz···th···
    • 《PS···OL···CA···ED···NE》
    • 2023年
    • 期刊

    Ba···ro···An···ge···ne···ex···s ···id···if···eu··· c···el···s ···oc···ed···th···ff···ng···ve···of···ic··· r··· a···de···op···ve···ra···-a···ng···er···ut··· t···od···te···ti···y ···hi···he···ne···l ···wo···.M···od···ec···ph···ol···ca···or···at···of···ic··· w··· e···ua··· u···g ···ne···nc···al···ap···(M··· i···5 ···lt···it···if···in···ev··· o···ui···e ···k.···ri···ME···ca···ng···ar···ip···s ···pl···d ···od···ed···fe···at···mp···it···so···ti···Ta··· M···da···we···so···e-···al···d ···th···am···(3···8 ··· f···ue···, ···ro···me···re··· e···ta···n-···ib···on···la···. ···am···ca···l ···el··· w···us···to···al···e ···fe···ce···n ···ne···vi···es···at···be···en···sk···ou··· A···oo···f-···ce··· o···-l···l,···lo···tu···of···ve···gh···sk···rt···pa··· e···in···ch···es··· g···a ···er···te···dm···st···io···f ···am··· (··· m···g)···n ···AR···ta···is···it···ap···an···su···de···ea···n ···ec···Re···ts···li··· s···-a···ci···on···it···ea···we···st···ge···n ··· h···es···ui···e ···k ···up···la···e ···al···th···gr···s,···ic···id···t ···fe···ro···ac···th··· H···er···mm···ow···fo···el···ea···co···re···o ···f-···e ···oc···io···wa···ou···in···e ···it···on··· c···ex···r ··· h···es···is···ro···an···he···su···an···os···io···in···at···or··· f···th···ow··· r··· g···p.···nn···iv··· e···ma··· b···ee···he···re···ns···ff···nt···ed···e ···he···ri···gr··· f··· t···fu···sa···e.···pl···t ···oc···io···wi···de··· w··· n···af···te···y ···am···, ··· e···nc···ga··· p···r ··· f···d ··· s···-d···h ···oc···io···in···e ···t ···ul···os···et···ne···mp···d ···ba···in···on···si···Di···re···al···pl···t ···ni···e ···ce···ng··· l··· a···de··· a···ar···o ···li···d ···su···de···sk···ig···gh···g ··· n··· f···ob···ti···me···re···f ···ci··· s···es···ha···co···ra···s ···t ···ul··· g···a ···iv···, ···ti···ar···in···e ···ul···ma···el···it···te···sk···in···lt···ls···v ···nt···er···CT···43···, ···00···11···on···si···Di···re···al···pl···t ···ni···e ···ce···ng··· l··· a···de··· a···ar···o ···li···d ···su···de···sk···ig···gh···g ··· n··· f···ob···ti···me···re···f ···ci··· s···es···ha···co···ra···s ···t ···ul··· g···a ···iv···, ···ti···ar···in···e ···ul···ma···el···it···te···sk···in···lt···ls···v ···nt···er···CT···43···, ···00···11··

    ...
  • 7.In···mm···on···tr··· a···de···ss···: ···ex···ra···n ···ke···in··· t···ap···ic···of···

    • 关键词:
    • Ketamine; depression; stress; inflammation; treatment-resistantdepression; anhedonia;TREATMENT-RESISTANT DEPRESSION; C-REACTIVE PROTEIN; NF-KAPPA-B;ANIMAL-MODELS; MICROGLIAL ACTIVATION; SERUM INTERLEUKIN-6; KYNURENINEPATHWAY; DOWN-REGULATION; DOUBLE-BLIND; GLUTAMATE

    Well-established animal models of depression have described a proximal relationship between stress and central nervous system (CNS) inflammation - a relationship mirrored in the peripheral inflammatory biomarkers of individuals with depression. Evidence also suggests that stress-induced proin-flammatory states can contribute to the neurobiology of treatment-resistant depression. Interestingly, ketamine, a rapid-acting antidepressant, can partially exert its therapeu-tic effects via anti-inflammatory actions on the hypothala-mic-pituitary adrenal (HPA) axis, the kynurenine pathway or by cytokine suppression. Further investigations into the relationship between ketamine, inflammation and stress could provide insight into ketamine's unique therapeutic mechanisms and stimulate efforts to develop rapid-acting, anti-inflammatory-based antidepressants.

    ...
  • 9. Sk···an···M,···rt···z-···ti···, ···ac···, ···ul···, ···ri···z-···la··· M···or··· J···Ta···P,···pp···, ···in··· S···ag··· A···es···mo···, ···ar···Sa···ez··· A···ak···, ···he···nn··· B···he···t ···Be···t ···Be···re···-Y···a ···Ce···nt···Ar···ga··· C···e ···Co···er··· D···ev···, ···la···r ··· G···et···N,···ov···va··· G···ha··· O···ro··· M···an··· K···st···Ee··· L···ur··· M···Ma···ne··· M···in···Ca···il···JC···en···a-···ri···z ···Mi··· M···oo···HP···ul···a ···Mu···er··· P···er··· P···e ···Ra···an···, ···te···, ···ri···z-···zq··· C···in··· C···al···ic··· G···z ··· S···bi···GT···n ···18···Re···io···ip···tw··· t···MD···PD···an···ua···y ···Li··· A···rg···ul···en··· s···y ···32···pa···nt···Pa···ns···sm···Re···ed···so···rs···2,···3−··· D··· 1···01···.p···re···s.···8.···02··

  • 排序方式:
  • 8
  • /